News
SLDB
9.29
+4.85%
0.43
Weekly Report: what happened at SLDB last week (0622-0626)?
Weekly Report · 10h ago
Solid Biosciences initial beneficial ownership filing shows RA Capital Management stake
PUBT · 4d ago
Weekly Report: what happened at SLDB last week (0615-0619)?
Weekly Report · 06/22 09:08
Is Solid Biosciences (NASDAQ:SLDB) In A Good Position To Invest In Growth?
Simply Wall St · 06/19 10:26
Sophia Genetics, Ormat Technologies And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Benzinga · 06/17 12:03
Weekly Report: what happened at SLDB last week (0608-0612)?
Weekly Report · 06/15 09:08
Solid Biosciences Shareholders Approve Directors and Share Increase
TipRanks · 06/10 21:05
Solid Biosciences shareholders approve charter amendment to double authorized common shares to 480 million
PUBT · 06/10 20:05
Weekly Report: what happened at SLDB last week (0601-0605)?
Weekly Report · 06/08 09:07
Analysts Offer Insights on Healthcare Companies: Vera Therapeutics (VERA) and Solid Biosciences (SLDB)
TipRanks · 06/05 13:30
Solid Biosciences Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 06/03 12:08
Solid Biosciences Price Target Raised to $25.00/Share From $20.00 by HC Wainwright & Co.
Dow Jones · 06/03 12:08
HC Wainwright & Co. Maintains Buy on Solid Biosciences, Raises Price Target to $25
Benzinga · 06/03 11:58
Solid Biosciences price target raised to $25 from $20 at H.C. Wainwright
TipRanks · 06/03 10:07
SOLID BIOSCIENCES INC. <SLDB.O>: H.C. WAINWRIGHT RAISES TARGET PRICE TO $25 FROM $20
Reuters · 06/03 10:03
U.S. RESEARCH ROUNDUP-Aveanna Healthcare, Palo Alto, Ulta Beauty
Reuters · 06/03 07:55
SOLID BIOSCIENCES AND NANOMOSAIC ANNOUNCE CO-MARKETING AGREEMENT TO ADVANCE GENE THERAPY DELIVERY AND ANALYTICS
Reuters · 06/02 11:00
Solid Biosciences grants 6,580 RSUs to new hire under inducement plan
PUBT · 06/01 20:09
SOLID BIOSCIENCES REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 06/01 20:05
Solid Biosciences CEO to present at Jefferies Global Healthcare Conference
PUBT · 06/01 12:06
More
Webull provides a variety of real-time SLDB stock news. You can receive the latest news about Solid Bioscience through multiple platforms. This information may help you make smarter investment decisions.
About SLDB
Solid Biosciences Inc. is a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases. The Company is focused on advancing a portfolio of gene therapy candidates including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy and additional assets for the treatment of genetic cardiac and neuromuscular disease. It also has two cardiac pipeline gene transfer programs, SGT-401 for BAG3-mediated DCM, which is in early preclinical development, and SGT-701 for RBM20 DCM, which is in the discovery stage. In addition to its gene transfer candidates, the Company has development programs focusing on platform technologies, including capsid libraries and dual gene expression, a technology that allows it to package multiple transgenes into one capsid.